Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Subclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapy
AuthorsAnne-Laure Mallard de La Varende; Ai-Ling Tian; Simon Thomas; Imran Lahmar; Meriem Messaoudene; Sijing Li; Omar Motiño; Hortense Guillaume-dit-Taunière; Valerio Iebba; Yoan Hurtado; Thao-Nguyen Pham; Cassandra Thélémaque; Miguel Araujo-Voces; Deborah Suissa; Pierre Ly; Ella Reich; Giacomo Vitali; Bryan Thierry Arlunno; Sylvere Durand; Fanny Aprahamian; Marion Leduc; Sabrina Forveille; Oliver Kepp; Carlos de la Calle-Fabregat; Angela Schippers; Norbert Wagner; Pierre-Edouard Fournier; Kenya Honda; Federica Marmorino; Chiara Cremolini; Saman Maleki Vareki; John G. Lenehan; Aurélien Marabelle; François-Xavier Danlos; Margaux Deligne; Caroline Truntzer; François Ghiringhelli; Anne H. Ree; Paula A. Bousquet; Sebastian Meltzer; Florent Ginhoux; Deklan Rummel; Yousi Fu; Robert A. Quinn; Carolina Alves Costa Silva; Roberto Iacovelli; Chiara Ciccarese; Serena Porcari; Arielle Elkrief; Bertrand Routy; Gianluca Ianiro; Lisa Derosa; Guido Kroemer; Marine Fidelle; Laurence Zitvogel
AffiliationsUniversité Paris-Saclay, Gustave Roussy (GRCC), ClinicObiome, Inserm UMR1367, Microbiota and Mucosal Immunity for Cancer Immunotherapy, 94805 Villejuif, France; Centre de recherche Du CHUM (CRCHUM), Montréal, QC H2W1T8, Canada; Centre de Recherche des Cordeliers, INSERM U1138, Équipe Labellisée – Ligue Nationale Contre le Cancer, Université Paris Cité, Sorbonne Université, 75006 Paris, France; Unidad de Excelencia, Instituto de Biomedicina y Genética Molecular de Valladolid, Consejo Superior de Investigaciones Científicas-Universidad de Valladolid, 47001 Valladolid, Spain; MetaGenoPolis, INRAe, Université Paris-Saclay 78350 Jouy en Josas, France; Université Paris-Saclay, INSERM US23, Analyse moléculaire, modélisation et imagerie de la maladie Cancéreuse, Plateformes de Métabolomique et de Criblage Cellulaire Haut Débit, 94805 Villejuif, France; Université Paris-Saclay, Gustave Roussy, U1356 Next Generation Immuno-Oncology Research, 94805 Villejuif, France; Klinik für Kinder- und Jugendmedizin, RWTH Universitätsklinikum Aachen, 52074 Aachen, Germany; IHU Méditerranée Infection, 13005 Marseille, France; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo 160-8582, Japan; RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan; Human Biology Microbiome Quantum Research Center (WPI-Bio2Q), Keio University, Tokyo 160-8582, Japan; Unit of Medical Oncology 2, University Hospital of Pisa, 56126 Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy; Verspeeten Family Cancer Centre, London Health Sciences Centre Research Institute, London, ON N6A5W9, Canada; Department of Oncology, Western University, London, ON N6A5W9, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON N6A5W9, Canada; Ontario Institute of Cancer Research, Toronto, ON M5G0A3, Canada; Université Paris-Saclay, Gustave Roussy, Drug Development Department (DITEP), 94805 Villejuif, France; Immunotherapy Translational Research Lab (LRTI), INSERM U1356, Center of Clinical Investigations in Biotherapies of Cancer (BIOTHERIS) INSERM CIC1428, 94805 Villejuif, France; Université Paris-Saclay, CentraleSupélec, Gustave Roussy, INSERM, Cancer Data Science Unit, IHU PRISM National Precision Medicine Center in Oncology, 94805 Villejuif, France; Université Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer Biology Transfer Platform, INSERM, CTM UMR 1231, TIRECs team, 21000 Dijon, France; Department of Medical Oncology, Georges François Leclerc Cancer Center-Unicancer, 21000 Dijon, France; Genomic and Immunotherapy Medical Institute, Dijon University Hospital, Dijon, France; University of Burgundy-Europe, 21000 Dijon, France; Institute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway; Department of Oncology, Akershus University Hospital, 1478 Lørenskog, Norway; Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA; Department of Microbiology, Genetics and Immunology, Michigan State University, East Lansing, MI 48824, USA; Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo 01309-001, Brazil; Department of Translational Medicine and Surgery, Università Cattolica Del Sacro Cuore, Facoltà di Medicina e Chirurgia, 00168 Roma, Italy; Department of Medical and Surgical Sciences, Comprehensive Cancer Center, Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Roma, Italy; Department of Medical and Surgical Sciences, UOC CEMAD Centro Malattie Dell'Apparato Digerente, Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario Gemelli IRCCS, 00168 Roma, Italy; Centre hospitalier de l'Université de Montréal (CHUM), Hematology-Oncology Division, Department of Medicine, H2W1T8 Montréal, QC, Canada; Institut Du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France
PD-1 blockade unleashes local hepatitis B virus-related B cell response inhibiting hepatocellular carcinoma
AuthorsShuling Chen; Yuanqi Wang; Jingying Chen; Wenxuan Xie; Jianyu Chen; Guanrui Liao; Xiaoxue Ren; Kai Lei; Yuting Zhang; Shu Wang; Ye Yang; Youmei Kang; Qiaoyi Chen; Yixi Wen; Jiaming Lai; Pengyuan Yang; Shunli Shen; Shaoqiang Li; Johnson Yiu-Nam Lau; Changjun Yin; Ming Kuang
AffiliationsCenter of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China; Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China; Institute of Precision Medicine, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China; Department of Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China; Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China; Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China; Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China; Key Laboratory of Epigenetic Regulation and Intervention, Institute of Biophysics, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Beijing 100101, China; Faculty of Sciences, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR; Institute for Cardiovascular Prevention, Ludwig-Maximilians-University, Munich, Germany
Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial
AuthorsZhiyuan Xu; Can Hu; Litao Yang; Pengfei Yu; Yanqiang Zhang; Jiahui Chen; Guoliang Zheng; Xiaodong Chen; Tao Zhang; Weiyang He; Xiangyu Meng; Panpan Yu; Yian Du; Xiaowen Liu; Youdong Liu; Yongxiang Wang; Xiaoxiao Wu; Siwei Pan; Ruolan Zhang; Shengjie Zhang; Zhirong Xiong; Wei Sun; Chuanxin Dong; Jiajun Liu; Yuexian Wu; Xiangdong Cheng
AffiliationsDepartment of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China; Department of Gastric Surgery, Liaoning Cancer Hospital, Shenyang, Liaoning, China; Department of Gastric Surgery, Sichuan Cancer Hospital, Chengdu, Sichuan, China; Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China; Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province, Hangzhou 310022, China; Medical Affairs, BeOne Medicines (Beijing) Co., Ltd., Beijing, China
Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms
AuthorsJeremy Wen; Anitria Cotton; Rashid Mehmood; Man Mohan; Trent Hall; Amber L. Broadhurst; Kevin Zhang; Yunusa Olufadi; Guolian Kang; Bridget Marcellino; John Mascarenhas; Ronald Hoffman; Laura J. Janke; Sandeep Gurbuxani; Gerard M. McGeehan; John D. Crispino
AffiliationsDepartment of Hematology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA; Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA; Tisch Cancer Institute, Icahn School of Medicine, New York, NY 10029, USA; Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA; Section of Hematopathology, University of Chicago, Chicago, IL 60637, USA; Syndax Pharmaceutics, Inc., New York, NY 10017, USA
GABA promotes resistance to immunotherapy in patients with TLS-positive tumors
AuthorsIsaias Hernández-Verdin; Anne Calvez; Cheng-Ming Sun; Antoine Bougoüin; Pierre Hirt; Eric Pinaud; Matthew J. Smith; Craig E. Wheelock; Virginie Verkarre; Yann-Alexandre Vano; Lucie Garnier; Théo Bouloudani; Guilhem Pupier; Dahbia Djaroun; Christian Wu; Asmat Ullah; Lucile Vanhersecke; Alban Bessede; Jean-Philippe Guegan; Laurence Albiges; Sylvère Durand; Guido Kroemer; Agusti Alentorn; Antoine Italiano; Stéphane Oudard; Catherine Sautès-Fridman; Wolf Herman Fridman
AffiliationsCentre de Recherche des Cordeliers, Sorbonne Université, INSERM, Université de Paris, 75006 Paris, France; Equipe labellisée Ligue Contre le Cancer, Centre de Recherche des Cordeliers, 75006 Paris, France; Institut du Cerveau-Paris Brain Institute-ICM, Inserm, Sorbonne Université, CNRS, 75013 Paris, France; Laboratoire Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), CNRS Unité Mixte de Recherche 7276, INSERM Unité 1262, Université de Limoges, Limoges, France; Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden; Department of Respiratory Medicine and Allergy, Karolinska University Hospital, 171 64 Stockholm, Sweden; Département de Pathologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris - Paris Centre, 75015 Paris, France; Université Paris Cité, 75006 Paris, France; Département d’Oncologie Médicale, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris - Paris Centre, 75015 Paris, France; Département d’Oncologie Médicale, Hôpital Foch, Suresnes France, Université de Versailles-Saint-Quentin-en-Yvelines, Versailles, France; Departement de Biopathologie, Institut Bergonié, Bordeaux, France; Explicyte, Bordeaux, France; Gustave Roussy, Université Paris-Saclay, Villejuif, France; Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France; Department of Neurology-2, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, Paris, France; Departement d’Oncologie Médicale, Institut Bergonié, Bordeaux, France; DITEP, Gustave Roussy, Villejuif, France; Université de Bordeaux, Bordeaux, France; PARCC, INSERM, Equipe Labellisée Ligue contre le Cancer, 75015 Paris, France
Spatial multi-omics landscape of colorectal cancer macro- and micrometastases
AuthorsYang Liu; Akshaya S. Jadhav; Yuwen Pan; Jianlong Liao; Isha Khanduri; Yunhe Liu; Riham Katkhuda; Wei Lu; Kyung Serk Cho; Zhimin Tong; Tieling Zhou; Kangyu Lin; Baohua Sun; Mei Jiang; Sharia D. Hernandez; Idania Carolina Lubo Julio; Patrick Brennan; Guangsheng Pei; Kai Yu; Yibo Dai; Tian Chu; Fuduan Peng; Khaja Khan; Saxon Rodriguez; Ling Xia; Youming Guo; Alicia Mejia; Sean W. Barnes; Ou Shi; Shreeya Indulkar; Alaa M.T. Mohamed; Natalie Wall Fowlkes; Timothy Newhook; Yun Shin Chun; Van K. Morris; David Menter; Dadi Jiang; John Paul Shen; Ryan Sun; Jean-Nicolas Vauthey; Ruoyan Li; Humam Kadara; Luisa M. Solis Soto; Scott Kopetz; Linghua Wang; Dipen Maru
AffiliationsDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of GI Radiation Oncology, Division of Radiation Oncology-Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for Cellular Language Intelligence, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX 77030, USA
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer
AuthorsJun Liao; Wenxiu Yao; Yan Yu; Anlin Li; Jie Huang; Xingya Li; Longhua Sun; Yongchang Zhang; Yongsheng Wang; Xiujuan Qu; Jun Zhao; Haiyong Wang; Weitao Zhuang; Liyang Hu; Xueyuan Chen; Lanlan Pang; Mengjuan Yang; Zexin Chen; Yaxiong Zhang; Ting Li; Wenyan Yu; Yiming Zeng; Jing Li; Ritesh Kataria; Gideon Blumenthal; Omobolaji Akala; Yanjun Liu; Yuping Shen; Junyou Ge; Shaodong Hong; Yunpeng Yang; Li Zhang; Wenfeng Fang
AffiliationsDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China; Department of Thoracic Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China; Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China; Department of Medical Oncology, Digestive and Urinary Unit, Hunan Cancer Hospital, Changsha, China; Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China; Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Department of Thoracic Oncology, the Cancer Center of the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China; Guangdong Research Center of Organoid Engineering and Technology, Guangzhou, China; Merck & Co., Inc., Rahway, NJ, USA; Clinical Research Center, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, China
Macrophage-mediated brain-bone marrow crosstalk promotes chronic stress-induced glioma growth
AuthorsZhengnan Yang; Jingtian Zhou; Fan Fei; Bohao Zheng; Sophie Xin Yang; Thomas M. Pearce; Peidong Zhang; Liang Huang; Jing Yue; Qiuhong Shen; Yiwei Du; Xiaoling Liao; Siyu Cheng; Li Li; Jian Liang; Luyao Liu; Xiaoxiao Wan; Michael D. Taylor; Joseph R. Ecker; Shengtao Zhou; Jeremy N. Rich; Linjie Zhao
AffiliationsDepartment of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second University Hospital, Department of Neurosurgery, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, P.R. China; Genomic Analysis Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA; Arc Institute, Palo Alto, CA, USA; Department of Neurosurgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, P.R. China; Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China; Business Administration of Business School, Sichuan University, Chengdu, P.R. China; Department of Pathology, Division of Neuropathology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Medical Records Management, West China Second University Hospital, Sichuan University, Chengdu, P.R. China; Division of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA; Pediatric Neuro-Oncology Research Program, Baylor College of Medicine, One Baylor Plaza, Houston, TX, USA; Division of Neurosurgery, Texas Children’s Hospital, One Baylor Plaza, Houston, TX, USA; Howard Hughes Medical Institute, The Salk Institute for Biological Studies, La Jolla, CA, USA; Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Chengdu, P.R. China; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
Spatial biomarker discovery via interpretable semantic learning in histopathology
AuthorsJunhao Liang; Xiaofeng Jiang; Nic Gabriel Reitsam; Tim Lenz; Li Zhang; Marco Gustav; Zunamys Itzell Carrero; Hannah Sophie Muti; Peter Neidlinger; Jan Clusmann; Laura Žigutytė; Vidhya Sainath; Fabian Wolf; Lisa A. Boardman; Amy J. French; Ellen L. Goode; Andrea Gsur; Stefanie Brezina; Marc J. Gunter; Robert Steinfelder; Tabitha Harrison; Ulrike Peters; Amanda I. Phipps; Philip Quirke; Nicholas P. West; Michael Hoffmeister; Hermann Brenner; Durgesh Wankhede; Jitendra Jonnagaddala; Nicholas Hawkins; Robyn L. Ward; Elena Fountzilas; Kyriaki Papadopoulou; George Fountzilas; Thierry André; Julien Taieb; Jean-François Emile; Magali Svrcek; Lingjie Kong; Jakob Nikolas Kather
AffiliationsElse Kroener Fresenius Center for Digital Health, Faculty of Medicine, TUD Dresden University of Technology, Dresden, Germany; State Key Laboratory of Precision Measurement Technology and Instruments, Department of Precision Instrument, Tsinghua University, Beijing 100084, China; Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China; Pathology, Faculty of Medicine, University of Augsburg, Augsburg, Germany; Bavarian Center for Cancer Research, BZKF, Augsburg, Germany; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; Department of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA; Center for Cancer Research, Medical University of Vienna, Vienna, Austria; Nutrition and Metabolism Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France; Cancer Epidemiology and Prevention Research Unit, School of Public Health, Imperial College London, London, UK; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Pathology & Data Analytics, Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, UK; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany; Cancer Prevention Graduate School, German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, NSW, Australia; Department of Medical Oncology, St Luke’s Clinic, Thessaloniki, Greece; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Thessaloniki, Greece; Medical Oncology, Institut Universitaire de Cancérologie AP-HP Sorbonne Université - Hôpital Saint-Antoine, Paris, France; Department of Gastroenterology and Digestive Oncology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, University of Paris Cité, 75015 Paris, France; Paris-Saclay University, Versailles SQY University, EA4340-BECCOH, Assistance Publique-Hôpitaux de Paris, Ambroise-Paré Hospital, Smart Imaging, Service de Pathologie, Boulogne, France; Sorbonne Université, LIMICS, INSERM UMRS 1142, Paris, France; Léon Bérard Comprehensive Cancer Center, Department of Pathology, Lyon, France; IDG/McGovern Institute for Brain Research, Tsinghua University, Beijing, China; Department of Medicine I, Faculty of Medicine, TUD Dresden University of Technology, Dresden, Germany; Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany; Department for Visceral, Thoracic and Vascular Surgery, University Hospital and Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; National Center for Tumor Diseases Dresden (NCT/UCC), A Partnership Between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, German Cancer Research Center (DKFZ), Heidelberg, Germany; Division of Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany; Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Internal Medicine III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany; European University Cyprus, Engomi, Cyprus
Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer
AuthorsRong Tang; Liquan Jin; Chen Chen; Yingna Liao; Dingru Li; Yangyi Li; Yueyue Chen; Yuan Liu; Qiong Du; Zeyin Rong; Jiaoshun Chen; Yubin Lei; Zijian Wu; Zhen Tan; Yufeng Wang; Haoyu Wang; Jin Xu; Wei Wang; Si Shi; Xianjun Yu
AffiliationsDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200030, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200030, China; Shanghai Pancreatic Cancer Institute, Shanghai 200032, China; Shanghai Key Laboratory of Precision Medicine for Pancreatic Cancer, Shanghai 200032, China; Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China; Department of Endoscopy, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, Zhejiang Province 310030, China; Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; Department of Hepatobiliary Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong, China; Clinical Medical College of Dali University, Dali, Yunnan 671003, China
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
